Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Accentia BioPharmaceuticals, Inc.
Accentia, Exaeris sign copromotion agreement for MD Turbo
May 8th, 2006
Teamm Pharmaceuticals, Inc., the specialty pharmaceutical division of Accentia BioPharmaceuticals, Inc., (ABPI), and Exaeris, Inc., the wholly owned subsidiary of Inyx, Inc., (IYXI) have finalized a co-promotion agreement through which the companies will co-market the MD Turbo, a novel breath-activated, dose-counting companion to meter dose inhalers (MDIs). MD Turbo will be available by prescription in the U.S. later this quarter. MD Turbo is the first commercialized product specifically designed to coordinate inspiration and MDI activation using patented i-Point technology. The technology enables the majority of the MDIs used today to trigger their...
Source: Biotech Week (2006-05-08)
|
